Breast cancer treatment and adverse cardiac events: what are the molecular mechanisms?.
Cardiotoxicity associated with breast cancer treatment is an important concern in the oncology clinic. Different types of anti-cancer therapies have recorded high rates of cardiac dysfunction in treated patients. Cardiac dysfunction linked to anthracyclines--one of the most common conventional chemotherapies--has extensively been described and several mechanisms have been proposed, although their mode of action is not fully understood even in cancer cells. The mediation of cardiac damage by reactive oxygen species stress is a recent hypothesis that has attracted a lot of interest, since it might explain the tissue-specific toxic effects of anthracyclines in the heart. Regarding molecular targeted tyrosine kinase inhibitors used in patients with human epidermal growth factor receptor type 2+ tumours (e.g., trastuzumab, lapatinib), it is the blockage of survival pathways required for a normal heart development and function that seems to lead to cardiac pathology. Both types of breast cancer treatment appear to trigger cardiotoxicity synergically, being patients under adjuvant therapy closely monitored. Given the complex nature of heart failure and of the pathways altered by anti-cancer drugs, global gene expression regulation is key in the heart disease process. MicroRNAs have been demonstrated to be small molecules with big roles as essential gene expression modulators. The great potential of microRNAs as biomarkers in the cardio-oncology field needs to be further explored before new microRNA-based diagnostic and therapeutic tools can be developed.
Hammersmith Hospital, London, UK. l.roca-alonso10@imperial.ac.uk
Laura
L
Roca-Alonso
Loredana
L
Pellegrino
Leandro
L
Castellano
Justin
J
Stebbing
D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004317:Doxorubicin / Q000009:adverse effects*; D005260:Female; D006331:Heart Diseases / Q000139:chemically induced*; D006801:Humans; D035683:MicroRNAs / Q000502:physiology; D058990:Molecular Targeted Therapy / Q000379:methods; D032383:Myocytes, Cardiac / Q000187:drug effects; D018384:Oxidative Stress / Q000502:physiology; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D017382:Reactive Oxygen Species; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000037:antagonists & inhibitors
D000903:Antibiotics, Antineoplastic; D004317:Doxorubicin; D035683:MicroRNAs; D011505:Protein-Tyrosine Kinases; D017382:Reactive Oxygen Species; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human